A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess
the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients
with active eosinophilic duodenitis. Subjects who complete the randomized, double-blind,
placebo-controlled treatment may have the option to receive 6 doses of open-label
lirentelimab (AK002) through the OLE Period of the study.